Want to see MIRM full AI Analyst Report?

Mirum Pharmaceuticals (MIRM) Stock Forecast & Price Target

801 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

MIRM Analyst Ratings

Strong Buy

12 Buy

0 Hold

0 Sell

Based on 12 analysts giving stock ratings to

Mirum

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

MIRM Stock 12 Month Forecast

Average Price Target

$154.00

▲(57.01% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for Mirum Pharmaceuticals in the last 3 months. The average price target is $154.00 with a high forecast of $200.00 and a low forecast of $130.00. The average price target represents a 57.01% change from the last price of $98.08.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"69":"$69","102":"$102","135":"$135","168":"$168","201":"$201"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":200,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$200.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":154,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$154.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":130,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$130.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[69,102,135,168,201],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,83.92,92.84923076923077,101.77846153846154,110.7076923076923,119.63692307692307,128.56615384615384,137.4953846153846,146.42461538461538,155.35384615384615,164.28307692307692,173.2123076923077,182.14153846153846,191.0707692307692,{"y":200,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,83.92,89.31076923076924,94.70153846153846,100.0923076923077,105.48307692307692,110.87384615384616,116.26461538461538,121.65538461538462,127.04615384615386,132.43692307692308,137.8276923076923,143.21846153846155,148.60923076923078,{"y":154,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,83.92,87.46461538461539,91.00923076923077,94.55384615384615,98.09846153846154,101.64307692307692,105.18769230769232,108.7323076923077,112.27692307692308,115.82153846153847,119.36615384615385,122.91076923076923,126.45538461538462,{"y":130,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":73,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.65,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.01,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.99,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.8,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.09,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.62,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.53,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.33,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":120.46,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.95,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":98.34,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.92,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$200.00

Average Price Target$154.00

Lowest Price Target$130.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

James Condulis

Stifel Nicolaus

$136→$156

Buy

59.05%

Upside

Reiterated

10/15/26

Analyst Lifts Mirum Price Target to $156 on De-Risked Pipeline and Strengthened Commercial Outlook

Gavin Clark-Gartner

Evercore ISI

$135→$146

Buy

48.86%

Upside

Reiterated

10/13/26

Mirum Pharmaceuticals price target raised to $146 from $135 at Evercore ISIMirum Pharmaceuticals price target raised to $146 from $135 at Evercore ISI

Yigal Nochomovitz

Citi

$160→$184

Buy

87.60%

Upside

Reiterated

10/13/26

Mirum Pharmaceuticals price target raised to $184 from $160 at CitiMirum Pharmaceuticals price target raised to $184 from $160 at Citi

Michael Ulz

Morgan Stanley

$137→$152

Buy

54.98%

Upside

Reiterated

10/13/26

Mirum Pharmaceuticals price target raised to $152 from $137 at Morgan StanleyMirum Pharmaceuticals price target raised to $152 from $137 at Morgan Stanley

Swayampakula Ramakanth

H.C. Wainwright

$195→$200

Buy

103.92%

Upside

Reiterated

10/12/26

Mirum Pharmaceuticals price target raised to $200 from $195 at H.C. WainwrightMirum Pharmaceuticals price target raised to $200 from $195 at H.C. Wainwright

Jessica Fye

J.P. Morgan

―

Buy

―

Reiterated

10/12/26

JPMorgan’s Fye Reaffirms Buy on Mirum as Strong Livmarli Phase III Data De-Risk sNDA Path and Support Billion-Dollar Peak Sales Outlook

Lisa Walter

RBC Capital

$135→$155

Buy

58.03%

Upside

Reiterated

10/08/26

Mirum Pharmaceuticals price target raised to $155 from $135 at RBC CapitalMirum Pharmaceuticals price target raised to $155 from $135 at RBC Capital

Brian Skorney

Robert W. Baird

$123→$130

Buy

32.54%

Upside

Reiterated

09/29/26

Mirum Pharmaceuticals price target raised to $130 from $123 at BairdMirum Pharmaceuticals price target raised to $130 from $123 at Baird

Joseph Schwartz

Leerink Partners

$154

Buy

57.01%

Upside

Reiterated

09/28/26

Buy Rating Backed by Strong Rare Liver Disease Franchise, Expanding Commercial Footprint, and Favorable Risk‑Reward at Mirum Pharmaceuticals

Joseph Thome

TD Cowen

$140

Buy

42.74%

Upside

Reiterated

09/28/26

TD Cowen Sticks to Its Buy Rating for Mirum Pharmaceuticals (MIRM)

Jonathan Wolleben

Citizens JMP

$146→$137

Buy

39.68%

Upside

Reiterated

08/06/26

Mirum Pharmaceuticals price target lowered to $137 from $146 at CitizensMirum Pharmaceuticals price target lowered to $137 from $146 at Citizens

Joshua Schimmer

Cantor Fitzgerald

$140

Buy

42.74%

Upside

Assigned

08/05/26

Mirum Pharmaceuticals (MIRM) Gets a Buy from Cantor Fitzgerald

Kalpit Patel

Wolfe Research

$145

Buy

47.84%

Upside

Initiated

05/19/26

Mirum Pharmaceuticals initiated with an Outperform at Wolfe ResearchMirum Pharmaceuticals initiated with an Outperform at Wolfe Research

Ryan Deschner

Raymond James

$164→$165

Buy

68.23%

Upside

Reiterated

05/07/26

Mirum Pharmaceuticals price target raised to $165 from $164 at Raymond JamesMirum Pharmaceuticals price target raised to $165 from $164 at Raymond James

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

James Condulis

Stifel Nicolaus

$136→$156

Buy

59.05%

Upside

Reiterated

10/15/26

Analyst Lifts Mirum Price Target to $156 on De-Risked Pipeline and Strengthened Commercial Outlook

Gavin Clark-Gartner

Evercore ISI

$135→$146

Buy

48.86%

Upside

Reiterated

10/13/26

Mirum Pharmaceuticals price target raised to $146 from $135 at Evercore ISIMirum Pharmaceuticals price target raised to $146 from $135 at Evercore ISI

Yigal Nochomovitz

Citi

$160→$184

Buy

87.60%

Upside

Reiterated

10/13/26

Mirum Pharmaceuticals price target raised to $184 from $160 at CitiMirum Pharmaceuticals price target raised to $184 from $160 at Citi

Michael Ulz

Morgan Stanley

$137→$152

Buy

54.98%

Upside

Reiterated

10/13/26

Mirum Pharmaceuticals price target raised to $152 from $137 at Morgan StanleyMirum Pharmaceuticals price target raised to $152 from $137 at Morgan Stanley

Swayampakula Ramakanth

H.C. Wainwright

$195→$200

Buy

103.92%

Upside

Reiterated

10/12/26

Mirum Pharmaceuticals price target raised to $200 from $195 at H.C. WainwrightMirum Pharmaceuticals price target raised to $200 from $195 at H.C. Wainwright

Jessica Fye

J.P. Morgan

―

Buy

―

Reiterated

10/12/26

JPMorgan’s Fye Reaffirms Buy on Mirum as Strong Livmarli Phase III Data De-Risk sNDA Path and Support Billion-Dollar Peak Sales Outlook

Lisa Walter

RBC Capital

$135→$155

Buy

58.03%

Upside

Reiterated

10/08/26

Mirum Pharmaceuticals price target raised to $155 from $135 at RBC CapitalMirum Pharmaceuticals price target raised to $155 from $135 at RBC Capital

Brian Skorney

Robert W. Baird

$123→$130

Buy

32.54%

Upside

Reiterated

09/29/26

Mirum Pharmaceuticals price target raised to $130 from $123 at BairdMirum Pharmaceuticals price target raised to $130 from $123 at Baird

Joseph Schwartz

Leerink Partners

$154

Buy

57.01%

Upside

Reiterated

09/28/26

Buy Rating Backed by Strong Rare Liver Disease Franchise, Expanding Commercial Footprint, and Favorable Risk‑Reward at Mirum Pharmaceuticals

Joseph Thome

TD Cowen

$140

Buy

42.74%

Upside

Reiterated

09/28/26

TD Cowen Sticks to Its Buy Rating for Mirum Pharmaceuticals (MIRM)

Jonathan Wolleben

Citizens JMP

$146→$137

Buy

39.68%

Upside

Reiterated

08/06/26

Mirum Pharmaceuticals price target lowered to $137 from $146 at CitizensMirum Pharmaceuticals price target lowered to $137 from $146 at Citizens

Joshua Schimmer

Cantor Fitzgerald

$140

Buy

42.74%

Upside

Assigned

08/05/26

Mirum Pharmaceuticals (MIRM) Gets a Buy from Cantor Fitzgerald

Kalpit Patel

Wolfe Research

$145

Buy

47.84%

Upside

Initiated

05/19/26

Mirum Pharmaceuticals initiated with an Outperform at Wolfe ResearchMirum Pharmaceuticals initiated with an Outperform at Wolfe Research

Ryan Deschner

Raymond James

$164→$165

Buy

68.23%

Upside

Reiterated

05/07/26

Mirum Pharmaceuticals price target raised to $165 from $164 at Raymond JamesMirum Pharmaceuticals price target raised to $165 from $164 at Raymond James

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

KNSAKiniksa Pharmaceuticals

OMCLOmnicell

AXGNAxoGen

ONCBeOne Medicines

AHCOAdaptHealth

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Mirum Pharmaceuticals

3 Months

Gavin Clark-GartnerEvercore ISI

Success Rate

12/17 ratings generated profit

Average Return

+12.95%

Copying Gavin Clark-Gartner's trades and holding each position for 3 Months would result in 70.59% of your transactions generating a profit, with an average return of +12.95% per trade.

1 Year

Jonathan WollebenCitizens JMP

Success Rate

20/23 ratings generated profit

Average Return

+48.28%

Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 86.96% of your transactions generating a profit, with an average return of +48.28% per trade.

2 Years

Jonathan WollebenCitizens JMP

Success Rate

20/23 ratings generated profit

Average Return

+110.87%

Copying Jonathan Wolleben's trades and holding each position for 2 Years would result in 86.96% of your transactions generating a profit, with an average return of +110.87% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MIRM Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, MIRM has received 29 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. MIRM average Analyst price target in the past 3 months is 154.00.

Each month's total comprises the sum of three months' worth of ratings.

MIRM Financial Forecast

MIRM Earnings Forecast

Next quarter’s earnings estimate for MIRM is -$0.49 with a range of -$0.87 to $0.05. The previous quarter’s EPS was -$1.06. MIRM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year MIRM has Performed in-line its overall industry.

MIRM Sales Forecast

Next quarter’s sales forecast for MIRM is $178.08M with a range of $170.50M to $181.66M. The previous quarter’s sales results were $176.24M. MIRM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year MIRM has Performed in-line its overall industry.

MIRM Stock Forecast FAQ

What is MIRM’s average 12-month price target, according to analysts?

Based on analyst ratings, Mirum Pharmaceuticals Inc’s 12-month average price target is 154.00.

What is MIRM’s upside potential, based on the analysts’ average price target?

Mirum Pharmaceuticals Inc has 57.01% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is MIRM a Buy, Sell or Hold?

Mirum Pharmaceuticals Inc has a consensus rating of Strong Buy which is based on 12 buy ratings, 0 hold ratings and 0 sell ratings.

What is Mirum Pharmaceuticals Inc’s price target?

The average price target for Mirum Pharmaceuticals Inc is 154.00. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $200.00 ,the lowest forecast is $130.00. The average price target represents 57.01% Increase from the current price of $98.08.

What do analysts say about Mirum Pharmaceuticals Inc?

Mirum Pharmaceuticals Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of MIRM?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Mirum Pharmaceuticals (MIRM) Stock Forecast & Price Target

MIRM Analyst Ratings

MIRM Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Mirum Pharmaceuticals

MIRM Analyst Recommendation Trends

MIRM Financial Forecast

MIRM Earnings Forecast

MIRM Sales Forecast

MIRM Stock Forecast FAQ

Detailed List of Analyst Forecasts